S. Yu. Fedorova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
S. Yu. Fedorova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- D. E. Vybornykh
National Medical Research Center for Hematology, Ministry of Health of Russia
4 shared publications - Daria Aleksandrovna Koroleva
National Medical Research Center for Hematology
3 shared publications - Eduard G. Gemdzhian
National Medical Research Center for Hematology
3 shared publications - Elena Parovichnikova
National Medical Research Center of Hematology
3 shared publications - Eugene Eugeneevich Zvonkov
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
3 shared publications - G. A. Yatsyk
National Medical Research Center for Hematology
3 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 380–393
Intrathecal dexamethasone as an approach for immune effector cell-associated neurotoxicity syndrome after CAR T cell therapies
Introduction . The use of T-lymphocytes with a chimeric antigen receptor (Chimeric Antigen Receptor T-Cells, CAR T) has shown its effectiveness in the treatment of relapsed/refractory forms of B-cell acute lymphoblastic leukemia (B-ALL) with CNS involvement. A formidable complication of this treatment is immune effector cell-associated neurotoxicity syndrome (ICANS). Aim : to present clinical observations of patients with ICANS in whom, along with systemic administration of dexamethasone and anakinra, a therapeutic effect was achieved by intrathecal administration of dexamethasone. Main Findings . In 2 patients with relapsed B-ALL, ICANS developed after infusion of autologous anti-CD19 CAR T-lymphocytes. In both cases, the concentration of interleukin-6 (IL-6) in the cerebrospinal fl uid was many times higher than that in the blood, which indicated local production of the cytokine in the CNS. In addition to therapy with intravenous dexamethasone and anakinra, intrathecal administration of dexamethasone was performed, which led to rapid improvement of the patients’ condition.
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 380–393
Open AccessIntrathecal dexamethasone as an approach for immune effector cell-associated neurotoxicity syndrome after CAR T cell therapies
Introduction . The use of T-lymphocytes with a chimeric antigen receptor (Chimeric Antigen Receptor T-Cells, CAR T) has shown its effectiveness in the treatment of relapsed/refractory forms of B-cell acute lymphoblastic leukemia (B-ALL) with CNS involvement. A formidable complication of this treatment is immune effector cell-associated neurotoxicity syndrome (ICANS). Aim : to present clinical observations of patients with ICANS in whom, along with systemic administration of dexamethasone and anakinra, a therapeutic effect was achieved by intrathecal administration of dexamethasone. Main Findings . In 2 patients with relapsed B-ALL, ICANS developed after infusion of autologous anti-CD19 CAR T-lymphocytes. In both cases, the concentration of interleukin-6 (IL-6) in the cerebrospinal fl uid was many times higher than that in the blood, which indicated local production of the cytokine in the CNS. In addition to therapy with intravenous dexamethasone and anakinra, intrathecal administration of dexamethasone was performed, which led to rapid improvement of the patients’ condition.
- Open Access
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 120-132
Adherence to treatment in patients with multiple myeloma and pain syndrome
Background. Treatment adherence is one of the key factors influencing the therapy outcome in patients with multiple myeloma complicated by pain syndrome.Aim. To clarify the treatment adherence features in patients with multiple myeloma.Materials and methods. The data of 61 patients with pain syndrome associated with bortezomib-induced polyneuropathy and oral mucositis were studied. Men – 17 (27.9 %), women – 44 (72.1 %). Median age – 52 (31–67) years. Assessment of pain syndrome and psychometric parameters of patients was performed in hospital before autologous hematopoietic stem cell transplantation (1st point), on the 8th (2nd point) and 100th (3rd point) days after transplantation. Validated algometric and psychometric methods were used.Results. At each study point, patients with high adherence were grouped into 1st group, and patients with low adherence were grouped into 2nd group. At 1st point, statistically significant differences were noted between the groups in such indicators as quality of life / satisfaction and the degree of polyneuropathy. At the 2nd point, significant differences were found in the types of patient’s attitude toward illness: in the 1st group, adaptive types (harmonious, ergopathic) predominated, in the 2nd – maladaptive ones (anxious, neurasthenic, and sensitive). At 3rd point, a statistically significant difference was noted between the groups in the severity of mental disorders symptoms, the presence of which may be associated with decreased adherence to treatment, as well as the presence exclusively in the group with a low treatment adherence a maladaptive (egocentric) type of attitude toward illness.Conclusion. Adherence to treatment in patients with multiple myeloma complicated by pain syndrome is a complex problem that requires a multidisciplinary team of specialists, which should include hematologists, algologists, and mental health specialists (psychiatrists, medical psychologists).
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 120-132
Open AccessAdherence to treatment in patients with multiple myeloma and pain syndrome
Background. Treatment adherence is one of the key factors influencing the therapy outcome in patients with multiple myeloma complicated by pain syndrome.Aim. To clarify the treatment adherence features in patients with multiple myeloma.Materials and methods. The data of 61 patients with pain syndrome associated with bortezomib-induced polyneuropathy and oral mucositis were studied. Men – 17 (27.9 %), women – 44 (72.1 %). Median age – 52 (31–67) years. Assessment of pain syndrome and psychometric parameters of patients was performed in hospital before autologous hematopoietic stem cell transplantation (1st point), on the 8th (2nd point) and 100th (3rd point) days after transplantation. Validated algometric and psychometric methods were used.Results. At each study point, patients with high adherence were grouped into 1st group, and patients with low adherence were grouped into 2nd group. At 1st point, statistically significant differences were noted between the groups in such indicators as quality of life / satisfaction and the degree of polyneuropathy. At the 2nd point, significant differences were found in the types of patient’s attitude toward illness: in the 1st group, adaptive types (harmonious, ergopathic) predominated, in the 2nd – maladaptive ones (anxious, neurasthenic, and sensitive). At 3rd point, a statistically significant difference was noted between the groups in the severity of mental disorders symptoms, the presence of which may be associated with decreased adherence to treatment, as well as the presence exclusively in the group with a low treatment adherence a maladaptive (egocentric) type of attitude toward illness.Conclusion. Adherence to treatment in patients with multiple myeloma complicated by pain syndrome is a complex problem that requires a multidisciplinary team of specialists, which should include hematologists, algologists, and mental health specialists (psychiatrists, medical psychologists).
- Open Access
- 19 March 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (1) , 154-164
Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects
Background. One of the most common causes of peripheral neuropathy in multiple myeloma patients is bortezomib‑induced peripheral neuropathy (bIpN), which is clinically characterized by paresthesia, a burning sensation, numbness, and primarily pain in the limbs. This pain syndrome is often associated with the development of anxiety and depression. Aim. To study the pain syndrome associated with BIPN and determine the relationship between mental disorders and pain descriptors in patients with multiple myeloma at the completion stage of induction therapy and after autologous hematopoietic stem cell transplantation (auto‑HSCT). Materials and methods. From January 2023 to April 2024 a prospective study was conducted to examine pain and its relationship with psychopathological manifestations. The study included 48 patients (38 women and 10 men, median age 54 years) with multiple myeloma and diagnosed bIpN. pain syndrome and psychometric indicators were assessed using various validated algometric and psychometric techniques during hospitalization before auto‑HSCT and on day 100 after transplantation. Electroneuromyography was performed at the same time for an objective assessment of the studied parameters. Results. BIPN was diagnosed in 32 % of patients. pain intensity ranged from minimal to unbearable, With higher BIPN severity correlating with more vivid and diverse descriptions of the pain syndrome. pain localized in the fingers and toes predominated in 58 % of patients. The use of the pain detect questionnaire and the visual Analog Scale allowed for a detailed evaluation of changes in pain syndrome, revealing a statistically significant reduction in pain intensity 100 days after auto‑HSCT (p 0.05). A control electroneuromyography conducted 100 days after auto‑HSCT confirmedpartial or complete restoration of nerve fibers functional state. Based on the beck Anxiety and depression Inventory questionnaires completed by patients with pronounced pain syndrome, anxiety symptoms were identified in 6 cases (18 %), and depressive states in 8 cases (24 %). A study of patients’ psycho‑emotional states 100 days after auto‑HSCT showed a reduction in the frequency and severity of depressive states. However, unlike depression, anxiety persisted in the same patients. Conclusion. The conducted study, which testifies to the presence and persistence of psychoemotional disorders in a number of patients, indicates the need for a comprehensive approach to treatment, including not only pain therapy, but also psychoemotional support.
- 19 March 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (1) , 154-164
Open AccessBortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects
Background. One of the most common causes of peripheral neuropathy in multiple myeloma patients is bortezomib‑induced peripheral neuropathy (bIpN), which is clinically characterized by paresthesia, a burning sensation, numbness, and primarily pain in the limbs. This pain syndrome is often associated with the development of anxiety and depression. Aim. To study the pain syndrome associated with BIPN and determine the relationship between mental disorders and pain descriptors in patients with multiple myeloma at the completion stage of induction therapy and after autologous hematopoietic stem cell transplantation (auto‑HSCT). Materials and methods. From January 2023 to April 2024 a prospective study was conducted to examine pain and its relationship with psychopathological manifestations. The study included 48 patients (38 women and 10 men, median age 54 years) with multiple myeloma and diagnosed bIpN. pain syndrome and psychometric indicators were assessed using various validated algometric and psychometric techniques during hospitalization before auto‑HSCT and on day 100 after transplantation. Electroneuromyography was performed at the same time for an objective assessment of the studied parameters. Results. BIPN was diagnosed in 32 % of patients. pain intensity ranged from minimal to unbearable, With higher BIPN severity correlating with more vivid and diverse descriptions of the pain syndrome. pain localized in the fingers and toes predominated in 58 % of patients. The use of the pain detect questionnaire and the visual Analog Scale allowed for a detailed evaluation of changes in pain syndrome, revealing a statistically significant reduction in pain intensity 100 days after auto‑HSCT (p 0.05). A control electroneuromyography conducted 100 days after auto‑HSCT confirmedpartial or complete restoration of nerve fibers functional state. Based on the beck Anxiety and depression Inventory questionnaires completed by patients with pronounced pain syndrome, anxiety symptoms were identified in 6 cases (18 %), and depressive states in 8 cases (24 %). A study of patients’ psycho‑emotional states 100 days after auto‑HSCT showed a reduction in the frequency and severity of depressive states. However, unlike depression, anxiety persisted in the same patients. Conclusion. The conducted study, which testifies to the presence and persistence of psychoemotional disorders in a number of patients, indicates the need for a comprehensive approach to treatment, including not only pain therapy, but also psychoemotional support.
- Open Access
- 25 November 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (3) , 368-383
Biopsy-free diagnosis of primary diffuse large B-cell lymphoma of the central nervous system
Introduction. The use of invasive methods for diagnosing primary diffuse large B-cell lymphoma of the central nervous system (PDLBCL CNS) and primary vitreoretinal lymphoma (PVRL) is often associated with the development of severe neurological deficits and disability of patients. A promising direction in the diagnosis of PDLBCL CNS and PVRL is the use of non-invasive approaches based on molecular genetic methods for the determination of mutations in the MYD88 gene in the cerebrospinal fluid (CSF), vitreous fluid (VF) and free circulating tumor DNA (cfDNA) in blood serum.Aim: to present the potential of non-invasive diagnosis of PDLBCL CNS and PVRL.Main findings. The study included 6 patients (4 — PDLBCL CNS, 2 — PVRL). The average age was 64 (54–75) years. Despite increased cytosis in the CSF in all 4 patients with PDLBCL CNS, the tumor population was determined by flow cytometry in only half of the cases. According to a molecular genetic study, mutations in the MYD88 gene with an allelic load from 2.5% to 15% were detected in the genomic DNA of the CSF of all patients. In 2 patients with PVRL, mutations in the MYD88 gene were detected in VF with an allelic load of 4.2% and 6.6%, which was the only confirmation of the diagnosis. Currently, 5 patients have completed the treatment program and 1 is undergoing therapy. All 5 patients are in complete remission (CR) of the disease with follow-up periods from 1 to 8 months.
- 25 November 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (3) , 368-383
Open AccessBiopsy-free diagnosis of primary diffuse large B-cell lymphoma of the central nervous system
Introduction. The use of invasive methods for diagnosing primary diffuse large B-cell lymphoma of the central nervous system (PDLBCL CNS) and primary vitreoretinal lymphoma (PVRL) is often associated with the development of severe neurological deficits and disability of patients. A promising direction in the diagnosis of PDLBCL CNS and PVRL is the use of non-invasive approaches based on molecular genetic methods for the determination of mutations in the MYD88 gene in the cerebrospinal fluid (CSF), vitreous fluid (VF) and free circulating tumor DNA (cfDNA) in blood serum.Aim: to present the potential of non-invasive diagnosis of PDLBCL CNS and PVRL.Main findings. The study included 6 patients (4 — PDLBCL CNS, 2 — PVRL). The average age was 64 (54–75) years. Despite increased cytosis in the CSF in all 4 patients with PDLBCL CNS, the tumor population was determined by flow cytometry in only half of the cases. According to a molecular genetic study, mutations in the MYD88 gene with an allelic load from 2.5% to 15% were detected in the genomic DNA of the CSF of all patients. In 2 patients with PVRL, mutations in the MYD88 gene were detected in VF with an allelic load of 4.2% and 6.6%, which was the only confirmation of the diagnosis. Currently, 5 patients have completed the treatment program and 1 is undergoing therapy. All 5 patients are in complete remission (CR) of the disease with follow-up periods from 1 to 8 months.
- Open Access
- 16 November 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (3) , 398-409
Successful treatment of relapses of primary mediastinal large B-cell lymphoma with central nervous system involvement
Introduction. Relapses of primary mediastinal large B-cell lymphoma (PMBСL) with involvement of the central nervous system (CNS) are usually incurable. Therapy tactics in patients with PMBCL with relapse in the CNS have not been defined. Aim: to present clinical observations of the treatment of relapses of PMBCL with CNS involvement using the “R-PML-CNS-2022” protocol. Main findings. Two clinical observations of patients with relapses of PMBCL with involvement of the CNS are presented. In both cases, the “R-PML—CNS-2022” protocol was used as a second-line treatment, and a complete remission of the disease was achieved. In the first case, within 6 months after auto-HCT, maintenance therapy with pembrolizumab was performed. Complete remission of the disease continues for 15 months. In the second observation, maintenance therapy with pembrolizumab was also started, however, due to the development of autoimmune complications after 2 cycles, treatment was discontinued. Complete remission of the disease continues for 13 months. Conclusion. The development of a new strategy for the treatment of relapses of PMLCL with CNS lesion according to the “R-PML—CNS-2022” protocol is a potentially curative approach in this group of patients.
- 16 November 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (3) , 398-409
Open AccessSuccessful treatment of relapses of primary mediastinal large B-cell lymphoma with central nervous system involvement
Introduction. Relapses of primary mediastinal large B-cell lymphoma (PMBСL) with involvement of the central nervous system (CNS) are usually incurable. Therapy tactics in patients with PMBCL with relapse in the CNS have not been defined. Aim: to present clinical observations of the treatment of relapses of PMBCL with CNS involvement using the “R-PML-CNS-2022” protocol. Main findings. Two clinical observations of patients with relapses of PMBCL with involvement of the CNS are presented. In both cases, the “R-PML—CNS-2022” protocol was used as a second-line treatment, and a complete remission of the disease was achieved. In the first case, within 6 months after auto-HCT, maintenance therapy with pembrolizumab was performed. Complete remission of the disease continues for 15 months. In the second observation, maintenance therapy with pembrolizumab was also started, however, due to the development of autoimmune complications after 2 cycles, treatment was discontinued. Complete remission of the disease continues for 13 months. Conclusion. The development of a new strategy for the treatment of relapses of PMLCL with CNS lesion according to the “R-PML—CNS-2022” protocol is a potentially curative approach in this group of patients.
- Open Access
- 27 March 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (1) , 41-49
Neurological disorders in patients with thrombotic thrombocytopenic purpura
Aim: to analyze the first neurological manifestation in patient with thrombotic thrombocytopenic purpura (TTP). Material and methods. The appeals from physicians who suspected TTP were included in the study. The neurological symptoms in 40 patients with TTP were also analyzed. Results. Among 208 physician appeals about the suspicion of TTP and the referral of plasma samples for testing of ADAMTS13 activity, there were 2% of neurologists. The diagnosis of TTP was confirmed in 40 patients. 9 (22.5%) had no neurological symptoms, and 31 (77.5%) had neurological disorders. Patients with neurological symptoms were older than patients without neurological symptoms (median 37 years and 31 years, p = 0.006). Neurological symptoms were less frequently observed in pregnancy-associated TTP (p = 0.008). Among neurological symptoms there were speech disorders (40%), headache (30%), cognitive deficits (32.5%), depression of consciousness (22.5%), paresis (25%), sensation disorders (20.5%), seizures (10%). Magnetic resonance imaging/computed tomography (MRI/CT) revealed ischemic stroke in 47.5%, hemorrhagic stroke in 15%. In 6 patients, despite neurological symptoms, no pathology was detected with MRI/CT. In 4 patients, in the absence of neurological symptoms, MRI/CT revealed ischemic foci in the brain. 8 patients died: 2 patients died from sepsis, 6 - from ischemic stroke. In surviving patients, neurological symptoms regressed after remission. Conclusion. Neurological symptoms are detected in most patients with TTP. Brain MRI/CT should be performed in all patients with TTP
- 27 March 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (1) , 41-49
Open AccessNeurological disorders in patients with thrombotic thrombocytopenic purpura
Aim: to analyze the first neurological manifestation in patient with thrombotic thrombocytopenic purpura (TTP). Material and methods. The appeals from physicians who suspected TTP were included in the study. The neurological symptoms in 40 patients with TTP were also analyzed. Results. Among 208 physician appeals about the suspicion of TTP and the referral of plasma samples for testing of ADAMTS13 activity, there were 2% of neurologists. The diagnosis of TTP was confirmed in 40 patients. 9 (22.5%) had no neurological symptoms, and 31 (77.5%) had neurological disorders. Patients with neurological symptoms were older than patients without neurological symptoms (median 37 years and 31 years, p = 0.006). Neurological symptoms were less frequently observed in pregnancy-associated TTP (p = 0.008). Among neurological symptoms there were speech disorders (40%), headache (30%), cognitive deficits (32.5%), depression of consciousness (22.5%), paresis (25%), sensation disorders (20.5%), seizures (10%). Magnetic resonance imaging/computed tomography (MRI/CT) revealed ischemic stroke in 47.5%, hemorrhagic stroke in 15%. In 6 patients, despite neurological symptoms, no pathology was detected with MRI/CT. In 4 patients, in the absence of neurological symptoms, MRI/CT revealed ischemic foci in the brain. 8 patients died: 2 patients died from sepsis, 6 - from ischemic stroke. In surviving patients, neurological symptoms regressed after remission. Conclusion. Neurological symptoms are detected in most patients with TTP. Brain MRI/CT should be performed in all patients with TTP
- Open Access
- 21 May 2020
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 65 (2) , 138-153-153
Combined head injuries in hemophilia patients with signs of victim behaviour
Background. Combined injuries involving brain damage represent the most severe and life-threatening conditions in hemophilia patients. These injuries are characterised by specific situational and behavioural circumstances indicating the presence of victim behaviour in such patients.Aim. To analyse the influence of victim behaviour in hemophilia patients on the formation of combined neurosurgical trauma and the choice of neurosurgical and traumatological treatment approaches.Materials and methods. Twenty five patients (20 patients with hemophilia A and 5 patients with hemophilia B) were included in the study. The patients suffered the following injuries: craniocerebral injuries — 68 (100.0 %); bone fractures — 18 (26.6 %); hematomas of the soft tissues of the face, upper and lower extremities, as well as bruised, lacerated wounds — 50 (73.4 %).Results. The following types of victim behaviour were identified in the hemophilia patients: paranoid — 7 (28.0 %), dependent — 8 (32.0 %), dissociative — 6 (24.0 %) and antisocial — 4 (16.0 %). The patients underwent hemostatic therapy with coagulation factor VIII or IX concentrates and surgical (neurosurgical and/or traumatological) treatment of the injuries associated with victim behaviour. In 51 (75.0 %) cases there was delayed medical care, which was the reason for the complicated course of the post-traumatic period. It was revealed that the best treatment results in patients with severe injuries, including craniocerebral traumas, were achieved in cases where medical assistance was provided in the first three hours after injury. As a result of the treatment, the majority of the patients demonstrated regression of the clinical manifestations of the injury.Conclusions. The proposed tactics for the diagnosis and neurosurgical/traumatological treatment of hemophilia patients with signs of victim behaviour, in whom combined brain injuries are detected, includes a comprehensive assessment of medical history data, clinical and laboratory examination, as well as determination of diagnostic criteria for the choice of patient-specific surgical techniques. It is proposed to use the number of patients’ return visits related to their victim behaviour as a quantitative assessment of the degree of victimization.Conflict of interest: the authors declare no conflict of interest.
- 21 May 2020
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 65 (2) , 138-153-153
Open AccessCombined head injuries in hemophilia patients with signs of victim behaviour
Background. Combined injuries involving brain damage represent the most severe and life-threatening conditions in hemophilia patients. These injuries are characterised by specific situational and behavioural circumstances indicating the presence of victim behaviour in such patients.Aim. To analyse the influence of victim behaviour in hemophilia patients on the formation of combined neurosurgical trauma and the choice of neurosurgical and traumatological treatment approaches.Materials and methods. Twenty five patients (20 patients with hemophilia A and 5 patients with hemophilia B) were included in the study. The patients suffered the following injuries: craniocerebral injuries — 68 (100.0 %); bone fractures — 18 (26.6 %); hematomas of the soft tissues of the face, upper and lower extremities, as well as bruised, lacerated wounds — 50 (73.4 %).Results. The following types of victim behaviour were identified in the hemophilia patients: paranoid — 7 (28.0 %), dependent — 8 (32.0 %), dissociative — 6 (24.0 %) and antisocial — 4 (16.0 %). The patients underwent hemostatic therapy with coagulation factor VIII or IX concentrates and surgical (neurosurgical and/or traumatological) treatment of the injuries associated with victim behaviour. In 51 (75.0 %) cases there was delayed medical care, which was the reason for the complicated course of the post-traumatic period. It was revealed that the best treatment results in patients with severe injuries, including craniocerebral traumas, were achieved in cases where medical assistance was provided in the first three hours after injury. As a result of the treatment, the majority of the patients demonstrated regression of the clinical manifestations of the injury.Conclusions. The proposed tactics for the diagnosis and neurosurgical/traumatological treatment of hemophilia patients with signs of victim behaviour, in whom combined brain injuries are detected, includes a comprehensive assessment of medical history data, clinical and laboratory examination, as well as determination of diagnostic criteria for the choice of patient-specific surgical techniques. It is proposed to use the number of patients’ return visits related to their victim behaviour as a quantitative assessment of the degree of victimization.Conflict of interest: the authors declare no conflict of interest.
- Open Access
- 2 April 2020
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- No. 1,p. 20-29
Cognitive impairment in patients with hematological malignancies at a long-term period after the transplantation of allogeneic hematopoietic stem cells
A comprehensive assessment of clinical, clinico-psychopathological, neurological, neuropsychological and instrumental examinations in a single study allows for a more detailed study of cognitive impairments in patients with CSC at a long-term period (12-15 months) after the transplantation of allogeneic hematopoietic stem cells.Purpose. Assessment of cognitive impairments in patients with hematological malignancies at a long-term period after the transplantation of allogeneic hematopoietic stem cells.Materials and methods. Clinical, psychopathological, clinical, psychological, neuropsychological, neurophysiological and neurovisual methods were used to examine 36 patients with various hematological malignancies in the period of 12-15 months after allo-HSCT. Statistical data analysis was performed using the methods of descriptive statistics, analysis of contingency tables and dispersive (with repeated measurements) analysis.Results and discussion. At a long-term period of the study (12-15 months), it was found that cognitive impairments are largely eliminated under the influence of a temporary factor, as well as the treatment of associated conditions (mental disorders, infectious complications, etc.). However, their level does not reach the normal (or close to them) values characteristics of the pre-transplant stage. Among the causes of this phenomenon, mention may be made of the organic lesions of the central nervous system, which are recorded during EEG, CEP, MRI / CT studies, and toxic encephalopathy due to exposure to chemotherapeutic and immunosuppressive drugs.Conclusion. The dynamics of cognitive impairments in general reflects the dynamics of the multifactor effects of various hazards accompanying the transplantation of allogeneic hematopoietic stem cells on the central nervous system. In this case, it can be stated with confidence that the allo-HSCT procedure in the overwhelming majority of cases does not lead to critical cognitive impairments.
- 2 April 2020
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- No. 1,p. 20-29
Open AccessCognitive impairment in patients with hematological malignancies at a long-term period after the transplantation of allogeneic hematopoietic stem cells
A comprehensive assessment of clinical, clinico-psychopathological, neurological, neuropsychological and instrumental examinations in a single study allows for a more detailed study of cognitive impairments in patients with CSC at a long-term period (12-15 months) after the transplantation of allogeneic hematopoietic stem cells.Purpose. Assessment of cognitive impairments in patients with hematological malignancies at a long-term period after the transplantation of allogeneic hematopoietic stem cells.Materials and methods. Clinical, psychopathological, clinical, psychological, neuropsychological, neurophysiological and neurovisual methods were used to examine 36 patients with various hematological malignancies in the period of 12-15 months after allo-HSCT. Statistical data analysis was performed using the methods of descriptive statistics, analysis of contingency tables and dispersive (with repeated measurements) analysis.Results and discussion. At a long-term period of the study (12-15 months), it was found that cognitive impairments are largely eliminated under the influence of a temporary factor, as well as the treatment of associated conditions (mental disorders, infectious complications, etc.). However, their level does not reach the normal (or close to them) values characteristics of the pre-transplant stage. Among the causes of this phenomenon, mention may be made of the organic lesions of the central nervous system, which are recorded during EEG, CEP, MRI / CT studies, and toxic encephalopathy due to exposure to chemotherapeutic and immunosuppressive drugs.Conclusion. The dynamics of cognitive impairments in general reflects the dynamics of the multifactor effects of various hazards accompanying the transplantation of allogeneic hematopoietic stem cells on the central nervous system. In this case, it can be stated with confidence that the allo-HSCT procedure in the overwhelming majority of cases does not lead to critical cognitive impairments.
- Open Access
- 12 December 2019
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 64 (4) , 447–461-461
HIGH-DOSE CHEMOTHERAPY FOR PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM. INTERIM RESULTS OF THE CNS-2015 PROTOCOL
Introduction. Induction chemotherapy (CT) for primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) is based on the use of methotrexate in high doses. An optimal consolidation strategy involves high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (auto-HSCT). The most effective conditioning regimen comprises a combination of chemotherapy agents including thiotepa.Aim. To present the authors’ experience of applying auto-HSCT/TBC in patients with primary DLBCL of the CNS.Methods. The prospective study CNS-2015 was carried out among 20 patients aged 20–52 years (median 42 years old) from 2015 to 2019. The male/female ratio came to 13/7. The somatic status of 17 (85 %) patients was 0–1 on the ECOG scale. Only 3 (15 %) patients showed the somatic status of 4 points. According to the criteria of the MSKCC prognostic system, 18 (90 %) and 2 (10 %) patients were assigned to the low-risk and medium-risk groups, respectively.Results. All patients included in the study received 3–5 cycles of chemotherapy with high doses of methotrexate, vincristine, procarbazine and rituximab (R-MPV), as well as underwent auto-HSCT following TBC-based conditioning regimen (thiotepa, busulfan, cyclophosphamide). Prior to auto-HSCT, 15 and 5 out of 20 patients having completed induction chemotherapy achieved complete remission and partial remission, respectively. Following auto-HSCT, complete remission was achieved in 5 patients with an initial partial response to treatment. All patients underwent temozolomide maintenance therapy for 2 years. With a median follow-up of 17 (1–46) months, 18 patients are alive and in remission. Two patients, who relapsed 4 and 5 months after auto-HSCT and achieved no response to the second line of chemotherapy and radiation therapy, died 24 and 26 months after auto-HSCT.Conclusion. R-MPV is an effective treatment for patients with primary DLBCL of CNS, which is not accompanied by severe toxicity. The use of high-dose chemotherapy with TBC allows a high remission rate to be achieved. The mortality associated with treatment in the group of patients included in the study came to 0 %.
- 12 December 2019
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 64 (4) , 447–461-461
Open AccessHIGH-DOSE CHEMOTHERAPY FOR PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM. INTERIM RESULTS OF THE CNS-2015 PROTOCOL
Introduction. Induction chemotherapy (CT) for primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) is based on the use of methotrexate in high doses. An optimal consolidation strategy involves high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (auto-HSCT). The most effective conditioning regimen comprises a combination of chemotherapy agents including thiotepa.Aim. To present the authors’ experience of applying auto-HSCT/TBC in patients with primary DLBCL of the CNS.Methods. The prospective study CNS-2015 was carried out among 20 patients aged 20–52 years (median 42 years old) from 2015 to 2019. The male/female ratio came to 13/7. The somatic status of 17 (85 %) patients was 0–1 on the ECOG scale. Only 3 (15 %) patients showed the somatic status of 4 points. According to the criteria of the MSKCC prognostic system, 18 (90 %) and 2 (10 %) patients were assigned to the low-risk and medium-risk groups, respectively.Results. All patients included in the study received 3–5 cycles of chemotherapy with high doses of methotrexate, vincristine, procarbazine and rituximab (R-MPV), as well as underwent auto-HSCT following TBC-based conditioning regimen (thiotepa, busulfan, cyclophosphamide). Prior to auto-HSCT, 15 and 5 out of 20 patients having completed induction chemotherapy achieved complete remission and partial remission, respectively. Following auto-HSCT, complete remission was achieved in 5 patients with an initial partial response to treatment. All patients underwent temozolomide maintenance therapy for 2 years. With a median follow-up of 17 (1–46) months, 18 patients are alive and in remission. Two patients, who relapsed 4 and 5 months after auto-HSCT and achieved no response to the second line of chemotherapy and radiation therapy, died 24 and 26 months after auto-HSCT.Conclusion. R-MPV is an effective treatment for patients with primary DLBCL of CNS, which is not accompanied by severe toxicity. The use of high-dose chemotherapy with TBC allows a high remission rate to be achieved. The mortality associated with treatment in the group of patients included in the study came to 0 %.
- Open Access
- 11 July 2019
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- No. 2,p. 20-36
Cognitive impairments in patients with hematological malignancies prior and after allogeneic hematopoietic stem cells transplantation
The treatment of patients with hematological malignancies is often complicated by a number of negative side effects, which include mental disorders, among which cognitive impairment occupies a special place. Psychopathological, psychological, neuropsychological, neurophysiological and neurovisual methods were used to examine 46 patients with various hematological malignancies during periods prior to allo-HSCT, 1-3 months after allo-HSCT, and 6 months after transplantation. When statistical analysis of data was performed correlation and multivariate analyzes. Patients at each stage of the study identified cognitive impairment caused by a combination of risk factors — the presence of a hematological malignancy, the encephalotropic activity of chemotherapy drugs, and mental, neurological disorders. The characteristic and stable dynamics of CN in the post-transplantation period is traced — a sharp decline in cognitive functions in almost all indicators at once in the early post-transplant period with their gradual recovery by 6 months after allo-HSCT. The attitude of patients to cognitive deficiency also changes during the period of treatment: from anozognosic and hyponozognosic at the pre-transplantation stage to hypernosognostic at long-term periods after allo-HSCT.
- 11 July 2019
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- No. 2,p. 20-36
Open AccessCognitive impairments in patients with hematological malignancies prior and after allogeneic hematopoietic stem cells transplantation
The treatment of patients with hematological malignancies is often complicated by a number of negative side effects, which include mental disorders, among which cognitive impairment occupies a special place. Psychopathological, psychological, neuropsychological, neurophysiological and neurovisual methods were used to examine 46 patients with various hematological malignancies during periods prior to allo-HSCT, 1-3 months after allo-HSCT, and 6 months after transplantation. When statistical analysis of data was performed correlation and multivariate analyzes. Patients at each stage of the study identified cognitive impairment caused by a combination of risk factors — the presence of a hematological malignancy, the encephalotropic activity of chemotherapy drugs, and mental, neurological disorders. The characteristic and stable dynamics of CN in the post-transplantation period is traced — a sharp decline in cognitive functions in almost all indicators at once in the early post-transplant period with their gradual recovery by 6 months after allo-HSCT. The attitude of patients to cognitive deficiency also changes during the period of treatment: from anozognosic and hyponozognosic at the pre-transplantation stage to hypernosognostic at long-term periods after allo-HSCT.